341 related articles for article (PubMed ID: 19351653)
1. Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
Breustedt B; Blanchardon E; Berard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
Radiat Prot Dosimetry; 2009 Feb; 134(1):38-48. PubMed ID: 19351653
[TBL] [Abstract][Full Text] [Related]
2. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy.
Breustedt B; Blanchardon E; Bérard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
Health Phys; 2010 Oct; 99(4):547-52. PubMed ID: 20838097
[TBL] [Abstract][Full Text] [Related]
3. Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: biokinetics and dosimetric approaches.
Fritsch P; Grappin L; Guillermin AM; Fottorino R; Ruffin M; Mièle A
Radiat Prot Dosimetry; 2007; 127(1-4):120-4. PubMed ID: 17562647
[TBL] [Abstract][Full Text] [Related]
4. Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments.
Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Abram MC; Renault D; Fattal E; Benech H; Deverre JR; Poncy JL
Radiat Res; 2009 Jun; 171(6):674-86. PubMed ID: 19580474
[TBL] [Abstract][Full Text] [Related]
5. Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
James AC; Sasser LB; Stuit DB; Glover SE; Carbaugh EH
Radiat Prot Dosimetry; 2007; 127(1-4):449-55. PubMed ID: 18227077
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA.
Sérandour AL; Grémy O; Fréchou M; Renault D; Poncy JL; Fritsch P
Radiat Res; 2008 Aug; 170(2):208-15. PubMed ID: 18666819
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective?
Taylor DM; Hodgson SA; Stradling N
Radiat Prot Dosimetry; 2007; 127(1-4):469-71. PubMed ID: 17556346
[TBL] [Abstract][Full Text] [Related]
8. Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms.
Sérandour AL; Tsapis N; Gervelas C; Grillon G; Fréchou M; Deverre JR; Bénech H; Fattal E; Fritsch P; Poncy JL
Radiat Prot Dosimetry; 2007; 127(1-4):472-6. PubMed ID: 17562654
[TBL] [Abstract][Full Text] [Related]
9. Developing a physiologically based approach for modeling plutonium decorporation therapy with DTPA.
Kastl M; Giussani A; Blanchardon E; Breustedt B; Fritsch P; Hoeschen C; Lopez MA
Int J Radiat Biol; 2014 Nov; 90(11):1062-7. PubMed ID: 24844369
[TBL] [Abstract][Full Text] [Related]
10. Improved Modeling of Plutonium-DTPA Decorporation.
Dumit S; Avtandilashvili M; Strom DJ; McComish SL; Tabatadze G; Tolmachev SY
Radiat Res; 2019 Feb; 191(2):201-210. PubMed ID: 30566387
[TBL] [Abstract][Full Text] [Related]
11. Enhanced decorporation of plutonium by DTPA encapsulated in small PEG-coated liposomes.
Phan G; Le Gall B; Grillon G; Rouit E; Fouillit M; Benech H; Fattal E; Deverre JR
Biochimie; 2006 Nov; 88(11):1843-9. PubMed ID: 16860919
[TBL] [Abstract][Full Text] [Related]
12. Plutonium-DTPA Model Application with USTUR Case 0269.
Konzen K; Brey R; Miller S
Health Phys; 2016 Jan; 110(1):59-65. PubMed ID: 26606066
[TBL] [Abstract][Full Text] [Related]
13. MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy.
Fritsch P; Grémy O; Hurtgen C; Bérard P; Grappin L; Poncy JL
Radiat Prot Dosimetry; 2011 Mar; 144(1-4):371-5. PubMed ID: 21131659
[TBL] [Abstract][Full Text] [Related]
14. Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action.
Grémy O; Laurent D; Coudert S; Griffiths NM; Miccoli L
Radiat Res; 2016 Jun; 185(6):568-79. PubMed ID: 27195610
[TBL] [Abstract][Full Text] [Related]
15. Modelling DTPA therapy following Am contamination in rats.
Kastl M; Grémy O; Lamart S; Giussani A; Li WB; Hoeschen C
Radiat Environ Biophys; 2023 Nov; 62(4):483-495. PubMed ID: 37831188
[TBL] [Abstract][Full Text] [Related]
16. USTUR whole body case 0262: 33-y follow-up of PuO2 in a skin wound and associated axillary node.
James AC; Sasser LB; Stuit DB; Wood TG; Glover SE; Lynch TP; Dagle GE
Radiat Prot Dosimetry; 2007; 127(1-4):114-9. PubMed ID: 18227076
[TBL] [Abstract][Full Text] [Related]
17. Development of a New Chelation Model: Bioassay Data Interpretation and Dose Assessment after Plutonium Intake via Wound and Treatment with DTPA.
Dumit S; Miller G; Klumpp JA; Poudel D; Bertelli L; Waters TL
Health Phys; 2020 Dec; 119(6):715-732. PubMed ID: 33196524
[TBL] [Abstract][Full Text] [Related]
18. Development of the Plutonium-DTPA Biokinetic Model.
Konzen K; Brey R
Health Phys; 2015 Jun; 108(6):565-73. PubMed ID: 25905517
[TBL] [Abstract][Full Text] [Related]
19. Validation of a system of models for plutonium decorporation therapy.
Dumit S; Avtandilashvili M; McComish SL; Strom DJ; Tabatadze G; Tolmachev SY
Radiat Environ Biophys; 2019 May; 58(2):227-235. PubMed ID: 30627772
[TBL] [Abstract][Full Text] [Related]
20. Three plutonium chelation cases at Los Alamos National Laboratory.
Bertelli L; Waters TL; Miller G; Gadd MS; Eaton MC; Guilmette RA
Health Phys; 2010 Oct; 99(4):532-8. PubMed ID: 20838095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
